Thermo Fisher Scientific Inc. $TMO Shares Sold by Los Angeles Capital Management LLC

Los Angeles Capital Management LLC trimmed its position in Thermo Fisher Scientific Inc. (NYSE:TMO) by 42.8% during the 2nd quarter, HoldingsChannel.com reports. The firm owned 2,153 shares of the medical research company’s stock after selling 1,613 shares during the period. Los Angeles Capital Management LLC’s holdings in Thermo Fisher Scientific were worth $873,000 at the end of the most recent quarter.

Other institutional investors have also recently made changes to their positions in the company. Nuveen LLC acquired a new stake in Thermo Fisher Scientific during the first quarter worth $532,360,000. EdgePoint Investment Group Inc. purchased a new position in shares of Thermo Fisher Scientific during the 1st quarter worth $172,139,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its position in shares of Thermo Fisher Scientific by 13.6% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 2,750,923 shares of the medical research company’s stock worth $1,368,859,000 after purchasing an additional 329,974 shares during the last quarter. Auto Owners Insurance Co lifted its position in Thermo Fisher Scientific by 6,773.5% in the first quarter. Auto Owners Insurance Co now owns 288,000 shares of the medical research company’s stock valued at $143,309,000 after buying an additional 283,810 shares during the last quarter. Finally, Alliancebernstein L.P. boosted its stake in Thermo Fisher Scientific by 18.3% during the first quarter. Alliancebernstein L.P. now owns 1,766,067 shares of the medical research company’s stock worth $878,795,000 after buying an additional 272,747 shares during the period. Hedge funds and other institutional investors own 89.23% of the company’s stock.

Thermo Fisher Scientific Trading Down 1.3%

NYSE:TMO opened at $580.19 on Friday. Thermo Fisher Scientific Inc. has a 12-month low of $385.46 and a 12-month high of $610.97. The firm has a market cap of $217.98 billion, a PE ratio of 33.52, a price-to-earnings-growth ratio of 3.27 and a beta of 0.82. The company has a current ratio of 1.50, a quick ratio of 1.11 and a debt-to-equity ratio of 0.62. The stock has a fifty day moving average price of $526.16 and a 200 day moving average price of $466.66.

Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings results on Wednesday, October 22nd. The medical research company reported $5.79 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.50 by $0.29. Thermo Fisher Scientific had a return on equity of 16.97% and a net margin of 15.02%.The company had revenue of $11.12 billion for the quarter, compared to analyst estimates of $10.90 billion. During the same quarter last year, the company earned $5.28 EPS. Thermo Fisher Scientific’s revenue for the quarter was up 4.9% compared to the same quarter last year. Thermo Fisher Scientific has set its FY 2025 guidance at 22.600-22.860 EPS. Sell-side analysts anticipate that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, January 15th. Shareholders of record on Monday, December 15th will be given a $0.43 dividend. The ex-dividend date of this dividend is Monday, December 15th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 0.3%. Thermo Fisher Scientific’s dividend payout ratio is currently 9.94%.

Thermo Fisher Scientific declared that its Board of Directors has initiated a share buyback plan on Thursday, November 6th that allows the company to repurchase $5.00 billion in shares. This repurchase authorization allows the medical research company to repurchase up to 2.4% of its shares through open market purchases. Shares repurchase plans are typically a sign that the company’s leadership believes its stock is undervalued.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on the stock. UBS Group boosted their price target on shares of Thermo Fisher Scientific from $500.00 to $590.00 and gave the company a “neutral” rating in a research note on Thursday, October 23rd. Royal Bank Of Canada set a $561.00 target price on Thermo Fisher Scientific and gave the company an “outperform” rating in a research report on Tuesday, September 2nd. Leerink Partners raised their price target on Thermo Fisher Scientific from $545.00 to $580.00 and gave the stock an “outperform” rating in a research report on Wednesday, October 22nd. Hsbc Global Res downgraded Thermo Fisher Scientific from a “strong-buy” rating to a “hold” rating in a report on Thursday, July 24th. Finally, Cowen restated a “buy” rating on shares of Thermo Fisher Scientific in a report on Thursday, October 23rd. Nineteen investment analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $601.65.

Insider Activity

In other news, VP Lisa P. Britt sold 10,225 shares of Thermo Fisher Scientific stock in a transaction on Friday, November 7th. The shares were sold at an average price of $571.62, for a total transaction of $5,844,814.50. Following the completion of the sale, the vice president directly owned 14,145 shares of the company’s stock, valued at approximately $8,085,564.90. The trade was a 41.96% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Gianluca Pettiti sold 400 shares of the stock in a transaction on Friday, October 24th. The shares were sold at an average price of $574.15, for a total value of $229,660.00. Following the completion of the transaction, the executive vice president directly owned 21,152 shares in the company, valued at $12,144,420.80. This trade represents a 1.86% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 46,645 shares of company stock valued at $25,825,699 over the last quarter. Company insiders own 0.33% of the company’s stock.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.